Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.41 |
| ▸ | AQP1 | P29972 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290331 | 0.97 | PRKAB2 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5697279 | 0.87 | PRKAB2 (0.34) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3291283 | 0.83 | RXFP1 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL8035083 | 0.81 | DRD2 (0.35) | TAAR1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL8970254 | 0.80 | DRD2 (0.34) | TAAR1NOS3NOS1NOS2 | |
| SCHEMBL3291401 | 0.79 | RXFP1 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5793346 | 0.79 | AQP1 (0.42) | AQP1TAAR1 | |
| SCHEMBL3289081 | 0.77 | AQP1 (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3291449 | 0.76 | AQP1 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3291027 | 0.75 | TAAR1 (0.33) | TAAR1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | claimed |
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | claimed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | claimed |
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006000902-A1 | DIHYDROBENZOFURAN COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | HTR2C, HTR1A, HTR1B | PRKAB2 3708/4885PRKAG1 3468/4885PRKAA2 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.